Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 6896024, 12 pages
http://dx.doi.org/10.1155/2016/6896024
Review Article

Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options

1Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal
2ICVS/3B’s-PT Government Associate Laboratory, Braga/Guimarães, Campus of Gualtar, 4710-057 Braga, Portugal
3Laboratory of Medical Investigation (LIM) 14, Faculty of Medicine, University of São Paulo, 01246-903 São Paulo, SP, Brazil
4Molecular Oncology Research Centre, 14784-400 Barretos, SP, Brazil
5Surgery Department, Hospitalar Center Trás-os-Montes e Alto Douro, Unidade Hospitalar de Chaves, Avenida Dr. Francisco Sá Carneiro, 5400-279 Chaves, Portugal

Received 7 December 2015; Revised 17 May 2016; Accepted 4 July 2016

Academic Editor: Anthony Antoniou

Copyright © 2016 Daniela Rodrigues et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. E. R. Fearon and B. Vogelstein, “A genetic model for colorectal tumorigenesis,” Cell, vol. 61, no. 5, pp. 759–767, 1990. View at Publisher · View at Google Scholar · View at Scopus
  3. C. R. Boland, F. A. Sinicrope, D. E. Brenner, and J. M. Carethers, “Colorectal cancer prevention and treatment,” Gastroenterology, vol. 118, no. 2, pp. S115–S128, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Weisenberger, K. D. Siegmund, M. Campan et al., “CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer,” Nature Genetics, vol. 38, no. 7, pp. 787–793, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Gustavsson, G. Carlsson, D. MacHover et al., “A review of the evolution of systemic chemotherapy in the management of colorectal cancer,” Clinical Colorectal Cancer, vol. 14, no. 1, pp. 1–10, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. “NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer,” Version 22016, 2015.
  7. T. André, C. Boni, M. Navarro et al., “Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3109–3116, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. H.-J. Schmoll, T. Cartwright, J. Tabernero et al., “Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients,” Journal of Clinical Oncology, vol. 25, no. 1, pp. 102–109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Van Cutsem, R. Labianca, G. Bodoky et al., “Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3117–3125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Gill, C. L. Loprinzi, D. J. Sargent et al., “Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?” Journal of Clinical Oncology, vol. 22, no. 10, pp. 1797–1806, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Ciliberto, U. Prati, L. Roveda et al., “Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials,” Oncology Reports, vol. 27, no. 6, pp. 1849–1856, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. Z.-M. Wang, Y.-Y. Chen, F.-F. Chen, S.-Y. Wang, and B. Xiong, “Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: a meta-analysis,” European Journal of Surgical Oncology, vol. 41, no. 9, pp. 1197–1203, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Colucci, V. Gebbia, G. Paoletti et al., “Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a Multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 4866–4875, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Souglakos, N. Androulakis, K. Syrigos et al., “FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG),” British Journal of Cancer, vol. 94, no. 6, pp. 798–805, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Falcone, S. Ricci, I. Brunetti et al., “Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1670–1676, 2007. View at Publisher · View at Google Scholar
  16. J. Cassidy, S. Clarke, E. Díaz-Rubio et al., “Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 2006–2012, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Van Cutsem, C.-H. Köhne, E. Hitre et al., “Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 360, no. 14, pp. 1408–1417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. U. McDermott, J. R. Downing, and M. R. Stratton, “Genomics and the continuum of cancer care,” The New England Journal of Medicine, vol. 364, no. 4, pp. 340–350, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Sobrero, A. Guglielmi, F. Grossi, F. Puglisi, and C. Aschele, “Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy,” Seminars in Oncology, vol. 27, no. 5, pp. 72–77, 2000. View at Google Scholar · View at Scopus
  21. P. G. Johnston, H.-J. Lenz, C. G. Leichman et al., “Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors,” Cancer Research, vol. 55, no. 7, pp. 1407–1412, 1995. View at Google Scholar · View at Scopus
  22. S. Popat, A. Matakidou, and R. S. Houlston, “Thymidylate-synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis,” Journal of Clinical Oncology, vol. 22, no. 3, pp. 529–536, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. T. Pullarkat, J. Stoehlmacher, V. Ghaderi et al., “Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy,” Pharmacogenomics Journal, vol. 1, no. 1, pp. 65–70, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Kawakami and G. Watanabe, “Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene,” Cancer Research, vol. 63, no. 18, pp. 6004–6007, 2003. View at Google Scholar · View at Scopus
  25. K. Uchida, K. Hayashi, K. Kawakami et al., “Loss of Heterozygosity at the Thymidylate Synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene,” Clinical Cancer Research, vol. 10, no. 2, pp. 433–439, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Tsujitani, H. Saito, Y. Maeta et al., “Neoangiogenesis in patients with gastric carcinoma in relation to the expression of vascular endothelial growth factor and thymidine phosphorylase,” Anticancer Research, vol. 24, no. 3, pp. 1853–1859, 2004. View at Google Scholar · View at Scopus
  27. E. H. Slager, M. W. Honders, E. D. van der Meijden et al., “Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer,” Blood, vol. 107, no. 12, pp. 4954–4960, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. D.-J. Ye and J.-M. Zhang, “Research development of the relationship between thymidine phosphorylase expression and colorectal carcinoma,” Cancer Biology & Medicine, vol. 10, no. 1, pp. 10–15, 2013. View at Publisher · View at Google Scholar
  29. H. Uetake, W. Ichikawa, T. Takechi, M. Fukushima, Z. Nihei, and K. Sugihara, “Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer,” Clinical Cancer Research, vol. 5, no. 10, pp. 2836–2839, 1999. View at Google Scholar
  30. M. Kornmann, W. Schwabe, S. Sander et al., “Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil,” Clinical Cancer Research, vol. 9, no. 11, pp. 4116–4124, 2003. View at Google Scholar
  31. D. Salonga, M. Johnson, R. Metzger et al., “Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase,” Clinical Cancer Research, vol. 6, no. 4, pp. 1322–1327, 2000. View at Google Scholar
  32. K. Omura, “Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines,” International Journal of Clinical Oncology, vol. 8, no. 3, pp. 132–138, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. A. B. P. Van Kuilenburg, J. Haasjes, D. J. Richel et al., “Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene,” Clinical Cancer Research, vol. 6, no. 12, pp. 4705–4712, 2000. View at Google Scholar · View at Scopus
  34. P. D. Senter, K. S. Beam, B. Mixan, and A. F. Wahl, “Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug,” Bioconjugate Chemistry, vol. 12, no. 6, pp. 1074–1080, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Iyer, C. D. King, P. F. Whitington et al., “Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes,” The Journal of Clinical Investigation, vol. 101, no. 4, pp. 847–854, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Innocenti, S. D. Undevia, L. Iyer et al., “Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan,” Journal of Clinical Oncology, vol. 22, no. 8, pp. 1382–1388, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Liu, D. Cheng, Q. Kuang, G. Liu, and W. Xu, “Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in caucasians,” PLoS ONE, vol. 8, no. 3, article e58489, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Iyer, S. Das, L. Janisch et al., “UGT1A1∗28 polymorphism as a determinant of irinotecan disposition and toxicity,” Pharmacogenomics Journal, vol. 2, no. 1, pp. 43–47, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Cheng, M. Li, J. Hu et al., “UGT1A16 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians,” Cancer Chemotherapy and Pharmacology, vol. 73, no. 3, pp. 551–560, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Shirota, J. Stoehlmacher, J. Brabender et al., “ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy,” Journal of Clinical Oncology, vol. 19, no. 23, pp. 4298–4304, 2001. View at Google Scholar · View at Scopus
  41. M.-Y. Huang, H.-L. Tsai, C.-H. Lin et al., “Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy,” Journal of Surgical Oncology, vol. 108, no. 7, pp. 457–464, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Li, L. Zhu, L. Yao, L. Xia, and L. Pan, “Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy,” BMC Gastroenterology, vol. 14, no. 1, article 154, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Y. Kim, S. H. Seo, M. S. An et al., “ERCC1 as a predictive marker for FOLFOX chemotherapy in an adjuvant setting,” Annals of Coloproctology, vol. 31, no. 3, pp. 92–97, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. M.-X. Li, X.-Y. Bi, H. Zhao et al., “Excision repair cross-complementation group 1 is a prognostic biomarker in patients with colorectal cancer receiving chemotherapy,” Chinese Medical Journal, vol. 129, no. 5, pp. 586–593, 2016. View at Publisher · View at Google Scholar · View at Scopus
  45. J. J. Yu, K. B. Lee, C. Mu et al., “Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene,” International Journal of Oncology, vol. 16, no. 3, pp. 555–560, 2000. View at Google Scholar · View at Scopus
  46. A. Ruzzo, F. Graziano, F. Loupakis et al., “Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy,” Journal of Clinical Oncology, vol. 25, no. 10, pp. 1247–1254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Sun, A. Gong, and P. Liang, “Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients,” Tumor Biology, vol. 36, no. 3, pp. 1549–1559, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Ciardiello and G. Tortora, “EGFR antagonists in cancer treatment,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1160–1174, 2008. View at Publisher · View at Google Scholar
  49. D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer,” The New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. L. B. Saltz, N. J. Meropol, P. J. Loehrer Sr., M. N. Needle, J. Kopit, and R. J. Mayer, “Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1201–1208, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Lièvre, J.-B. Bachet, D. Le Corre et al., “KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer,” Cancer Research, vol. 66, no. 8, pp. 3992–3995, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Di Fiore, F. Blanchard, F. Charbonnier et al., “Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy,” British Journal of Cancer, vol. 96, no. 8, pp. 1166–1169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. W. De Roock, H. Piessevaux, J. De Schutter et al., “KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab,” Annals of Oncology, vol. 19, no. 3, pp. 508–515, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Van Cutsem, C.-H. Köhne, I. Láng et al., “Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status,” Journal of Clinical Oncology, vol. 29, no. 15, pp. 2011–2019, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Van Cutsem, H.-J. Lenz, C.-H. Köhne et al., “Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer,” Journal of Clinical Oncology, vol. 33, no. 7, pp. 692–700, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Bokemeyer, I. Bondarenko, J. T. Hartmann et al., “Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study,” Annals of Oncology, vol. 22, no. 7, pp. 1535–1546, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. T. S. Maughan, R. A. Adams, C. G. Smith et al., “Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial,” The Lancet, vol. 377, no. 9783, pp. 2103–2114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. K. M. Tveit, T. Guren, B. Glimelius et al., “Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study,” Journal of Clinical Oncology, vol. 30, no. 15, pp. 1755–1762, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. C. J. Allegra, J. M. Jessup, M. R. Somerfield et al., “American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2091–2096, 2009. View at Publisher · View at Google Scholar
  60. R. G. Amado, M. Wolf, M. Peeters et al., “Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1626–1634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. J.-Y. Douillard, S. Siena, J. Cassidy et al., “Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) Versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study,” Journal of Clinical Oncology, vol. 28, no. 31, pp. 4697–4705, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Di Nicolantonio, M. Martini, F. Molinari et al., “Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5705–5712, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Frattini, D. Balestra, S. Suardi et al., “Different genetic features associated with colon and rectal carcinogenesis,” Clinical Cancer Research, vol. 10, no. 12, pp. 4015–4021, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Rajagopalan, A. Bardelli, C. Lengauer, K. W. Kinzler, B. Vogelstein, and V. E. Velculescu, “Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status,” Nature, vol. 418, no. 6901, article 934, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. W. De Roock, B. Claes, D. Bernasconi et al., “Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis,” The Lancet Oncology, vol. 11, no. 8, pp. 753–762, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. C. Bokemeyer, E. V. Cutsem, P. Rougier et al., “Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials,” European Journal of Cancer, vol. 48, no. 10, pp. 1466–1475, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. J.-Y. Douillard, K. S. Oliner, S. Siena et al., “Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer,” The New England Journal of Medicine, vol. 369, no. 11, pp. 1023–1034, 2013. View at Publisher · View at Google Scholar
  68. M. Frattini, P. Saletti, E. Romagnani et al., “PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients,” British Journal of Cancer, vol. 97, no. 8, pp. 1139–1145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Sartore-Bianchi, M. Martini, F. Molinari et al., “PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies,” Cancer Research, vol. 69, no. 5, pp. 1851–1857, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. F. Perrone, A. Lampis, M. Orsenigo et al., “PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients,” Annals of Oncology, vol. 20, no. 1, pp. 84–90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. C. S. Karapetis, D. Jonker, M. Daneshmand et al., “PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17,” Clinical Cancer Research, vol. 20, no. 3, pp. 744–753, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Avraham and Y. Yarden, “Feedback regulation of EGFR signalling: decision making by early and delayed loops,” Nature Reviews Molecular Cell Biology, vol. 12, no. 2, pp. 104–117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. B. Jacobs, W. De Roock, H. Piessevaux et al., “Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab,” Journal of Clinical Oncology, vol. 27, no. 30, pp. 5068–5074, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Khambata-Ford, C. R. Garrett, N. J. Meropol et al., “Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab,” Journal of Clinical Oncology, vol. 25, no. 22, pp. 3230–3237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. M. V. Blagosklonny, “How avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy,” Cancer Biology & Therapy, vol. 4, no. 12, pp. 1307–1310, 2005. View at Publisher · View at Google Scholar
  76. P. S. Hegde, A. M. Jubb, D. Chen et al., “Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab,” Clinical Cancer Research, vol. 19, no. 4, pp. 929–937, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. H. Hayashi, T. Arao, K. Matsumoto et al., “Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma,” Oncotarget, vol. 5, no. 9, pp. 2588–2595, 2014. View at Publisher · View at Google Scholar
  78. J. M. Jürgensmeier, H.-J. Schmoll, J. D. Robertson et al., “Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy,” British Journal of Cancer, vol. 108, no. 6, pp. 1316–1323, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. M. A. Bruhn, A. R. Townsend, C. Khoon Lee et al., “Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer,” International Journal of Cancer, vol. 135, no. 3, pp. 731–741, 2014. View at Publisher · View at Google Scholar
  80. H.-L. Tsai, C.-H. Lin, C.-W. Huang et al., “Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 2, pp. 1900–1910, 2015. View at Google Scholar · View at Scopus
  81. F. Loupakis, C. Cremolini, A. Fioravanti et al., “Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer,” British Journal of Cancer, vol. 104, no. 8, pp. 1262–1269, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. C. Fischer, B. Jonckx, M. Mazzone et al., “Anti-PlGF Inhibits Growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels,” Cell, vol. 131, no. 3, pp. 463–475, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Pohl, A. El-Khoueiry, D. Yang et al., “Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy,” Pharmacogenomics Journal, vol. 13, no. 2, pp. 173–180, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. T. Purnak, E. Ozaslan, and C. Efe, “Molecular basis of colorectal cancer,” The New England Journal of Medicine, vol. 362, no. 13, pp. 1246–1247, 2010. View at Google Scholar · View at Scopus
  85. M. Koopman, G. A. M. Kortman, L. Mekenkamp et al., “Deficient mismatch repair system in patients with sporadic advanced colorectal cancer,” British Journal of Cancer, vol. 100, no. 2, pp. 266–273, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. C. M. Ribic, D. J. Sargent, M. J. Moore et al., “Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer,” The New England Journal of Medicine, vol. 349, no. 3, pp. 247–257, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. D. J. Sargent, S. Marsoni, G. Monges et al., “Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer,” Journal of Clinical Oncology, vol. 28, no. 20, pp. 3219–3226, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. A. D. Roth, S. Tejpar, M. Delorenzi et al., “Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial,” Journal of Clinical Oncology, vol. 28, no. 3, pp. 466–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. J. F. Flejou, T. André, B. Chibaudel et al., “Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSAIC study,” Journal of Clinical Oncology, vol. 31, supplement, abstract 3524, 2013. View at Google Scholar
  90. E. M. Webber, T. L. Kauffman, E. O'Connor, and K. Goddard, “Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy,” BMC Cancer, vol. 15, no. 1, article 156, 2015. View at Publisher · View at Google Scholar · View at Scopus